In clear cell renal cell carcinoma (ccRCC), the hypoxia-inducible PMP carbonic anhydrase IX (CA9) has been targeted with [177Lu-DOTA-hG250], enhancing immunotherapy efficacy and tumour selectivity [10]. The gene discussed is CA9; the disease is nonpapillary renal cell carcinoma.